Department of Biotechnology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, 3514799422, Iran.
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, 5166614766, Iran.
Cell Biol Int. 2020 Feb;44(2):368-380. doi: 10.1002/cbin.11243. Epub 2019 Oct 18.
Colorectal cancer (CRC) is one of the leading causes of death worldwide. Recently, the role of cancer stem cells (CSCs) has been highlighted as a crucial emerging factor in chemoresistance, cancer relapse, and metastasis. CD133 is a surface marker of CSCs and has been argued to have prognostic and therapeutic values in CRC along with its related pathways such as Wnt, Notch, and hedgehog. Several studies have successfully applied targeted therapies against CD133 in CRC models namely bispecific antibodies (BiAbs) and anti-Wnt and notch pathways agents. These studies have yielded initial promising results in this regard. However, none of the therapeutics have been used in the clinical setting and their efficacy and adverse effects profile are yet to be elucidated. This review aims to gather the old and most recent data on the prognostic and therapeutic values of CD133 and CD133-targeted therapies in CRC.
结直肠癌（CRC）是全球主要死因之一。最近，癌症干细胞（CSCs）的作用作为化疗耐药、癌症复发和转移的一个关键新兴因素而受到重视。CD133 是 CSCs 的表面标志物，其在 CRC 中的预后和治疗价值以及与其相关的通路（如 Wnt、Notch 和 Hedgehog）一直存在争议。一些研究已经成功地在 CRC 模型中应用针对 CD133 的靶向治疗方法，即双特异性抗体（BiAbs）和抗 Wnt 和 Notch 通路药物。这些研究在这方面取得了初步的有希望的结果。然而，这些治疗方法都没有在临床环境中使用，其疗效和不良反应特征仍有待阐明。本综述旨在收集有关 CD133 和 CD133 靶向治疗在 CRC 中的预后和治疗价值的旧有和最新数据。
